NEW YORK, Dec. 17, 2015 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of KaloBios Pharmaceuticals, Inc. ("KaloBios" or the "Company") (NASDAQ: KBIO). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at firstname.lastname@example.org or 212-697-6484.
This investigation concerns whether KaloBios Pharmaceuticals, Inc. and certain of its officers and/or directors have violated the Federal Securities Laws under the Securities Exchange Act of 1934 (the "Exchange Act").
On December 17, 2015, Martin Shkreli was arrested by federal agents for securities fraud on charges of using Retrophin Inc.'s stock, a company Shkreli founded in 2011, to pay off hedge fund debts from unrelated business dealings.
Following this news, KaloBios stock has fallen as much as $12.56, or 53%, pre market.
If you are aware of any facts relating to this investigation, or purchased shares of KaloBios Pharmaceuticals, Inc., you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | firstname.lastname@example.org
SOURCE Bronstein, Gewirtz & Grossman, LLC